^
    26d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=144, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    2ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=177, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2028 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    4ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2028 --> Nov 2028
    Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    5ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Nov 2028
    Trial completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    6ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2028 --> Aug 2028 | Trial primary completion date: May 2028 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    10ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=257, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Sep 2027 --> May 2028
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    11ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=232, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Sep 2027
    Trial completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    1year
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=231, Recruiting, Janssen Research & Development, LLC | N=111 --> 231 | Trial primary completion date: Feb 2028 --> Sep 2027
    Enrollment change • Trial primary completion date • Metastases
    |
    JNJ-6420
    1year
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2025 --> Feb 2028
    Trial primary completion date • Metastases
    |
    JNJ-6420
    over1year
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2026 --> Aug 2028
    Trial completion date
    |
    JNJ-6420
    almost2years
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    JNJ-6420
    2years
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | N=76 --> 111 | Trial completion date: Jul 2025 --> Oct 2025
    Enrollment change • Trial completion date • Metastases
    |
    JNJ-6420